Cargando…

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo

CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vincelette, Nicole D., Ding, Husheng, Huehls, Amelia M., Flatten, Karen S., Kelly, Rebecca L., Kohorst, Mira A., Webster, Jonathan, Hess, Allan D., Pratz, Keith W., Karnitz, Larry M., Kaufmann, Scott H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400938/ https://www.ncbi.nlm.nih.gov/pubmed/30837643 http://dx.doi.org/10.1038/s41598-019-40218-0

Ejemplares similares

Intra-S phase checkpoint kinase Chk1 dissociates replication proteins Treslin and TopBP1 through multiple mechanisms during replication stress
por: Kelly, Rebecca L., et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil
por: Geng, Liyi, et al.
Publicado: (2011)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
por: Lin, Tara L., et al.
Publicado: (2019)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML
por: Uy, Geoffrey L., et al.
Publicado: (2022)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
por: Fianchi, Luana, et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
por: Guolo, Fabio, et al.
Publicado: (2020)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES
por: Manghisi, Beatrice, et al.
Publicado: (2023)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
por: Bernal, Teresa, et al.
Publicado: (2023)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

The two-component system CpxA/CpxR is critical for full virulence in Actinobacillus pleuropneumoniae
por: Liu, Feng, et al.
Publicado: (2022)

Memorandum 351
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1983)

Safety of CPX4 Breast Tissue Expanders in Primary Reconstruction Patients
por: Maxwell, Daniel, et al.
Publicado: (2021)

Interactions of the CpxA sensor kinase and cognate CpxR response regulator from Yersinia pseudotuberculosis
por: Thanikkal, Edvin J, et al.
Publicado: (2012)

The CpxA/CpxR Two-Component System Affects Biofilm Formation and Virulence in Actinobacillus pleuropneumoniae
por: Li, Huan, et al.
Publicado: (2018)

The Virulence Effect of CpxRA in Citrobacter rodentium Is Independent of the Auxiliary Proteins NlpE and CpxP
por: Giannakopoulou, Natalia, et al.
Publicado: (2018)

The CpxA/CpxR two-component system mediates regulation of Actinobacillus pleuropneumoniae cold growth
por: Yao, Qing, et al.
Publicado: (2022)

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS
por: Mehta, Priyanka, et al.
Publicado: (2023)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
por: Cortes, Jorge E., et al.
Publicado: (2021)

P530: CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION
por: Riva, Carola, et al.
Publicado: (2023)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_s6ihrh202h2ksr71otthfoa7i5